Rapport Therapeutics (RAPP) financial statements
Net income was -$111M.
Free cash flow was -$88M.
The diluted share count rose 2486% over the period (dilution).
Income statement
Fiscal years, from Rapport Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Research and development | $28M | $61M | $95M |
| Selling, general and admin | $8M | $22M | $30M |
| Operating income | -$36M | -$83M | -$125M |
| Pre-tax income | -$35M | -$78M | — |
| Income tax | $10,000 | $0 | $0 |
| Net income | -$35M | -$78M | -$111M |
| EPS (diluted) | -$23.10 | -$3.78 | -$2.86 |
| Diluted shares | 2M | 21M | 39M |
Balance sheet
Fiscal years, from Rapport Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Cash and short-term investments | $147M | $305M | $490M |
| Receivables | — | — | $0 |
| Total current assets | $151M | $310M | $499M |
| Property, plant and equipment | $2M | $4M | $3M |
| Total assets | $155M | $315M | $512M |
| Total current liabilities | $9M | $9M | $19M |
| Total liabilities | $14M | $10M | $28M |
| Shareholders' equity | -$26M | $305M | $485M |
| Net debt | -$70M | -$57M | -$53M |
Cash flow
Fiscal years, from Rapport Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating cash flow | -$27M | -$65M | -$87M |
| Capital spending | $2M | $2M | $616,000 |
| Free cash flow | -$29M | -$67M | -$88M |
| Stock-based compensation | $4M | $10M | $19M |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for RAPP.
Open RAPP in InvestinglyQuestions
How much free cash flow does Rapport Therapeutics generate?
-$88M in fiscal 2025 (operating cash flow minus capital spending).
From Rapport Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.